Description of the website

The website of Uppsala Monitoring Centre is a member of the WHO-led project Vaccine Safety Net (VSN).

Uppsala Monitoring Centre (UMC) is an independent foundation that advances the science of pharmacovigilance globally and serves as a WHO Collaborating Centre supporting the WHO Programme for International Drug Monitoring.

UMC’s primary website contains information about the centre’s scientific, operational, educational, and communication support for national regulatory authorities, the pharmaceutical industry, and researchers involved in the post-marketing safety surveillance of medicines and vaccines.

The website provides information about UMC’s own activities to investigate the safety of medicines and vaccines and includes a repository of scientific publications that UMC staff have contributed to on pharmacovigilance topics, including signal detection, data science, and research methods. The website also contains information on UMC’s essential pharmacovigilance products and services, including VigiBase, the unique WHO global database of reported potential side effects of medicinal products, and WHODrug, the global standardised dictionary of drug names. More information is available in https://who-umc.org/about-uppsala-monitoring-centre/ 

Website’s sponsorship policy

UMC is an independent, self-funded, not-for-profit foundation, founded by WHO and the Swedish government in 1978. It is a WHO Collaborating Centre, which sustains its operations by providing essential pharmacovigilance tools and services, most notably the WHODrug Global portfolio of products. This funding model ensures UMC’s intellectual and scientific independence, sustainability, and freedom to pursue its own vision.

More information is available here: https://who-umc.org/about-uppsala-monitoring-centre/governance-and-funding/

Website’s content or editorial policy

Uppsala Reports contains articles created internally by UMC staff, including pharmacovigilance experts, medical clinicians, data scientists, communication specialists and technologists. The site also publishes content sourced from external stakeholders, primarily representatives of national and regional regulatory authorities, recognised academics and researchers, and other pharmacovigilance or health communication experts. The site contains a disclaimer to the effect that externally sourced submissions do not necessarily reflect the views of UMC. Nevertheless, all external submissions are reviewed by staff to ensure factual and editorial integrity. More information is available here: https://www.uppsalareports.org/subscribe/